← Back to Clinical Trials
RecruitingNCT06253468

Efficacy and Tolerability of Tested Formula After 3 Months of Treatment of Facial Hyperpigmentation of 3 Origins

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionHyperpigmentation
SponsorCosmetique Active International
Study TypeINTERVENTIONAL
PhaseN/A
Enrollment72
SexALL
Min Age18 Years
Max AgeN/A
Start Date2024-06-14
Completion2025-03
Interventions
tested product

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The objective of this study is to evaluate the efficacy, cosmetic acceptability and improvement of the stigmatization of the tested product (2039125 03) used bis in die (BID) for 3 months in adult patients suffering from mild to moderate melasma, or mild to moderate acne induced post-inflammatory hyperpigmentation, or solar lentigo.

Eligibility Criteria

Inclusion Criteria: * all phototypes * only one of the following pigmentary conditions on the face: epidermal or mixed, mild to moderate melasma; mild to moderate acne-induced PIHP; solar lentigo * female patient of childbearing potential must use one of the reliable methods of contraception and agree not to change it during the study * patient agreeing not to be exposed to ultraviolet radiation (UV), natural (sun) or artificial (tanning salon), during the study Exclusion Criteria: * female patient who gave birth less than 3 months prior to Day 0, who is pregnant, breast-feeding or who plans to become pregnant during the study * male patient with beard or facial hair, which would interfere with clinical evaluation or clinical procedure baseline) * patient with any inflammatory dermatosis of the face such as seborrheic dermatitis, rosacea etc. * severe melasma, dermal melasma * patient with facial pigmentary disorders other than those described in inclusion criteria * patient who has us

Related Trials